EP2480579A4 - METHODS OF TREATING INFLAMMATION - Google Patents

METHODS OF TREATING INFLAMMATION

Info

Publication number
EP2480579A4
EP2480579A4 EP10819481.2A EP10819481A EP2480579A4 EP 2480579 A4 EP2480579 A4 EP 2480579A4 EP 10819481 A EP10819481 A EP 10819481A EP 2480579 A4 EP2480579 A4 EP 2480579A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating inflammation
inflammation
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10819481.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2480579A2 (en
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of EP2480579A2 publication Critical patent/EP2480579A2/en
Publication of EP2480579A4 publication Critical patent/EP2480579A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP10819481.2A 2009-09-23 2010-09-23 METHODS OF TREATING INFLAMMATION Withdrawn EP2480579A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (2)

Publication Number Publication Date
EP2480579A2 EP2480579A2 (en) 2012-08-01
EP2480579A4 true EP2480579A4 (en) 2013-07-31

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10819481.2A Withdrawn EP2480579A4 (en) 2009-09-23 2010-09-23 METHODS OF TREATING INFLAMMATION

Country Status (9)

Country Link
EP (1) EP2480579A4 (enExample)
KR (1) KR20120105429A (enExample)
CN (1) CN102725311A (enExample)
AU (1) AU2010298249A1 (enExample)
BR (1) BR112012006468A2 (enExample)
CA (1) CA2773978A1 (enExample)
IN (1) IN2012DN02423A (enExample)
MX (1) MX2012003514A (enExample)
WO (1) WO2011038149A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
TW201605886A (zh) * 2013-11-14 2016-02-16 巴克斯特保健公司 作爲治療標靶的ｍｉｆ
AU2017231832B2 (en) 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
CA3123290A1 (en) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
KR20220166809A (ko) * 2020-03-11 2022-12-19 바이오라인알엑스 리미티드 급성 호흡곤란 증후군 및 바이러스 감염 치료를 위한 cxcr4 억제제
US20210338626A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2003213647A1 (en) * 2002-02-27 2003-09-09 Emory University Multimeric binding complexes
AU2003215732B2 (en) * 2002-03-01 2009-12-17 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2254597A4 (en) * 2008-03-20 2012-04-18 Carolus Therapeutics Inc TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FILIP ANA-MARIA ET AL: "Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 12, 20 March 2009 (2009-03-20), pages 7977 - 7985, XP002575465, ISSN: 0021-9258, [retrieved on 20090120], DOI: 10.1074/JBC.M808620200 *
JÜRGEN BERNHAGEN ET AL: "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 5, 5 March 2007 (2007-03-05), pages 587 - 596, XP008140753, ISSN: 1078-8956, DOI: 10.1038/NM1567 *
VERA PEDRO L ET AL: "Cyclophosphamide-Induced Cystitis Increases Bladder CXCR4 Expression and CXCR4-Macrophage Migration Inhibitory Factor Association", PLOS ONE, vol. 3, no. 12, December 2008 (2008-12-01), XP002699221, ISSN: 1932-6203 *
WEBER CHRISTIAN ET AL: "Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 42, October 2008 (2008-10-01), pages 16278 - 16283, XP002699220, ISSN: 0027-8424 *
WEBER ET AL: "Abstract: 559 CHEMOKINES AS THERAPEUTIC TARGETS IN ATHEROSCLEROSIS", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 2, 1 June 2009 (2009-06-01), pages e1684 - e1685, XP026781902, ISSN: 1567-5688, [retrieved on 20090601], DOI: 10.1016/S1567-5688(09)71632-0 *

Also Published As

Publication number Publication date
BR112012006468A2 (pt) 2016-08-09
EP2480579A2 (en) 2012-08-01
WO2011038149A3 (en) 2011-10-27
CA2773978A1 (en) 2011-03-31
MX2012003514A (es) 2012-04-19
CN102725311A (zh) 2012-10-10
KR20120105429A (ko) 2012-09-25
WO2011038149A2 (en) 2011-03-31
AU2010298249A1 (en) 2012-04-19
IN2012DN02423A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
IL207752A0 (en) Methods of treating inflammation
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
ZA201304280B (en) Treatment of jak2-mediated conditions
IL226401A0 (en) Methods for treating disorders related to @fgfBA
IL208354A0 (en) Methods of treatment
IL207439A0 (en) Methods of treating inflammatory pain
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
PL2435825T3 (pl) Sposoby leczenia chorób
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL214664A0 (en) Methods of treating hair related conditions
IL215592A0 (en) Compositions and methods for the treatment of inflammation
GB201018147D0 (en) Method of treatment
EP2643001A4 (en) METHOD OF TREATING CANCER
IL233111A0 (en) Preparations for the treatment of inflammation
IL206491A0 (en) Treatment of produce
IL256026B (en) Treatment methods
DK2473482T3 (en) Methods of treating orthomyxoviral infections
GB201003920D0 (en) Method of treatment
GB0901456D0 (en) Treatment of psoriasis
IL218230A0 (en) Method of treating cancer
ZA201108493B (en) Method of treating hair
GB201012926D0 (en) Compounds for treatment of inflammation
IL200753A0 (en) Treatment of psoriasis
GB0908101D0 (en) Treatment of stress
GB201018149D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DURON, SERGIO

Inventor name: WEBER, CHRISTIAN

Inventor name: SCHULTZ, JOSHUA, ROBERT

Inventor name: TURNER, COURT

Inventor name: VOLLRATH, BENEDIKT

Inventor name: BERNHAGEN, JURGEN

Inventor name: ZERNECKE, ALMA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130702

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101AFI20130624BHEP

Ipc: A61P 35/00 20060101ALI20130624BHEP

Ipc: C07K 14/435 20060101ALI20130624BHEP

Ipc: C07K 7/06 20060101ALI20130624BHEP

Ipc: C07K 7/08 20060101ALI20130624BHEP

Ipc: A61K 38/18 20060101ALI20130624BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140130